MedTrace Logo

High-dose ICE With Amifostine

NCT00003657 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2017-01-20

No results posted yet for this study

Summary

The purpose of the study is to evaluate the combination of amifostine and high dose chemotherapy with blood stem cell support. Amifostine is a druf developed to protect normal tissues against the toxicities of chemotherapy and radiotherapy and has reduced the side effects of chemotherapy given at conventional doses.

Conditions

Interventions

BIOLOGICAL

filgrastim

DRUG

Amifostine

DRUG

Carboplatin

DRUG

Etoposide

DRUG

Ifosfamide

PROCEDURE

peripheral blood stem cell transplantation

Sponsors & Collaborators

Principal Investigators

  • Paul G.G. Richardson, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1998-07-31
Primary Completion
2000-11-30
Completion
2002-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00003657 on ClinicalTrials.gov